MMMyrna Y. Munar

Myrna Y. Munar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Myrna Y. Munar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Harleen Singh

    2 shared publications
  • Sandra B. Earle

    Department of Pharmacy Practice Findlay University School of Pharmacy Findlay Ohio

    2 shared publications
  • Brandon Hayes-Lattin

    Department of Pharmacy Services, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, CR9-4, Portland, Oregon 97239,1 Department of Pharmacy Practice, Oregon State University/Oregon Health & Science University College of Pharmacy, 3303 SW Bond Avenue, CH12C, Portland, Oregon 97239,2 Bone Marrow Transplant Program, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 972393

    1 shared publication
  • Carolyn C. Brackett

    1 shared publication
  • Donna Belle

    1 shared publication
  • Ganesh Cherala

    Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA

    1 shared publication

Latest Publications

  • Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever

    by Joseph S. Bubalo, Myrna Y. Munar, Ganesh Cherala, Brandon Hayes-Lattin, Richard Maziarz

    Daptomycin is the first antibacterial agent of the cyclic lipopeptides with in vitro bactericidal activity against gram-positive organisms, including vancomycin-resistant enterococci, methicillin-resistant staphylococci, and glycopeptide-resistant Staphylococcus aureus . The pharmacokinetics of daptomycin were determined in 29 adult oncology patients with neutropenic fever. Serial blood samples were drawn at 0, 0.5, 1, 2, 4, 8, 12, and 24 h after the initial intravenous infusion of 6 mg/kg of body weight daptomycin. Daptomycin total and free plasma concentrations were determined by high-pressure liquid chromatography. Concentration-time data were analyzed by noncompartmental methods. The results (presented as means ± standard deviations and ranges, unless indicated otherwise) were as follows: the maximum concentration of drug in plasma ( C max ) was 49.04 ± 12.42 μg/ml (range, 21.54 to 75.20 μg/ml), the 24-h plasma concentration was 6.48 ± 5.31 μg/ml (range, 1.48 to 29.26 μg/ml), the area under the concentration-time curve (AUC) from time zero to infinity was 521.37 ± 523.53 μg·h/ml (range, 164.64 to 3155.11 μg·h/ml), the volume of distribution at steady state was 0.18 ± 0.05 liters/kg (range, 0.13 to 0.36 liters/kg), the clearance was 15.04 ± 6.09 ml/h/kg (range, 1.90 to 34.76 ml/h/kg), the half-life was 11.34 ± 14.15 h (range, 5.17 to 83.92 h), the mean residence time was 15.67 ± 20.66 h (range, 7.00 to 121.73 h), and the median time to C max was 0.6 h (range, 0.5 to 2.5 h). The fraction unbound in the plasma was 0.06 ± 0.02. All patients achieved C max /MIC and AUC from time zero to 24 h (AUC 0-24 )/MIC ratios for a bacteriostatic effect against Streptococcus pneumoniae . Twenty-seven patients (93%) achieved a C max /MIC ratio for a bacteriostatic effect against S. aureus , and 28 patients (97%) achieved an AUC 0-24 /MIC ratio for a bacteriostatic effect against S. aureus . Free plasma daptomycin concentrations were above the MIC for 50 to 100% of the dosing interval in 100% of patients for S. pneumoniae and 90% of patients for S. aureus . The median time to defervescence was 3 days from the start of daptomycin therapy. In summary, a 6-mg/kg intravenous infusion of daptomycin every 24 h was effective and well tolerated in neutropenic cancer patients.


  • Open Access

    Administration of Tobramycin in the Beginning of the Hemodialysis Session

    by Osama Hussein Kamel Mohamed, Ihab M. Wahba, Suzanne Watnick, Sandra B. Earle, William M. Bennett, James W. Ayres, Myrna Y. Munar

    Background: Aminoglycoside antibiotic efficacy is related to peak concentration (Cmax) and postantibiotic effect, whereas toxicity is directly related to body exposure as measured by area under the serum concentration versus time curve (AUC). On the basis of pharmacokinetic simulation models, tobramycin administration during the first 30 min of high-flux hemodialysis achieves similar Cmax but significantly lower AUC and prehemodialysis concentrations compared with conventional dosing in the last 30 min of hemodialysis.


    • 15 May 2007
      • Vol. 75  (10) , 1487-96

    Drug dosing adjustments in patients with chronic kidney disease.

    by Myrna Y Munar, Harleen Singh

    Chronic kidney disease affects renal drug elimination and other pharmacokinetic processes involved in drug disposition (e.g., absorption, drug distribution, nonrenal clearance [metabolism]). Drug dosing errors are common in patients with renal impairment and can cause adverse effects and poor outcomes. Dosages of drugs cleared renally should be adjusted according to creatinine clearance or glomerular filtration rate and should be calculated using online or electronic calculators. Recommended methods for maintenance dosing adjustments are dose reductions, lengthening the dosing interval, or both. Physicians should be familiar with commonly used medications that require dosage adjustments. Resources are available to assist in dosing decisions for patients with chronic kidney disease.


  • The Use of Wireless Laptop Computers for Computer-Assisted Learning in Pharmacokinetics

    by Myrna Y. Munar, Harleen Singh, Donna Belle, Carolyn C. Brackett, Sandra B. Earle

    Objective. To implement computer-assisted learning workshops into pharmacokinetics courses in a doctor of pharmacy (PharmD) program. Design. Workshops were designed for students to utilize computer...